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Objectives. We investigated the effect of aminophylline, an
antagonist of the adenosine P1 receptor, on cardiac pain experi-
enced during percutaneous transluminal coronary angioplasty
(PTCA).
Background. Adenosine may mediate cardiac pain because the
administration of adenosine provokes cardiac pain like angina.
However, it is not known whether endogenous adenosine released
during myocardial ischemia is responsible for cardiac pain.
Methods. This was a single-blind, placebo-controlled random-
ized study. Of 21 men with stable effort angina with one-vessel
coronary artery disease who underwent balloon inﬂation four
times during PTCA, 11 received intravenously administered amin-
ophylline before the fourth balloon inﬂation and the other 10 were
given saline solution. The severity of cardiac pain based on the
pain score and ST segment elevation on standard surface and
intracoronary electrocardiograms were assessed.
Results. All patients experienced cardiac pain during balloon
inﬂation. Aminophylline signiﬁcantly prolonged the duration of
both the symptom-free interval (from 42  13 to 64  27 s,
mean  SD, p < 0.05) and inﬂation time (from 79  23 to 103 
20 s, p < 0.05), and it signiﬁcantly reduced the pain score from
7.6  1.4 to 4.6  2.3 (p < 0.01). However, aminophylline did not
affect ST segment elevation. Saline solution did not affect any of
these variables. Balloon diameter and pressure were not different
between the third and the fourth inﬂation in either group.
Conclusions. Aminophylline signiﬁcantly reduced the severity
of cardiac pain during PTCA without affecting ST segment
elevation. These ﬁndings suggest that the activation of P1 recep-
tors by endogenous adenosine may be partially responsible for
cardiac pain during ischemia.
(J Am Coll Cardiol 1996;28:1725–31)
1996 by the American College of Cardiology
Cardiac pain is experienced during myocardial ischemia. The
sympathetic afferent neural pathway is considered to be in-
volved in the transmission of the cardiac pain that stimulates
cardiac sensory receptors (1). Although stimuli responsible for
cardiac pain have been debated for many decades (2,3), recent
clinical studies have demonstrated that the infusion of exoge-
nous adenosine provoked cardiac pain in healthy volunteers
(4) or in patients with stable effort angina (5) and that the
severity of adenosine-induced cardiac pain was reduced by
aminophylline, a potent antagonist of adenosine P1 receptors.
These ﬁndings suggested that cardiac pain is probably pro-
duced by chemical stimulation of adenosine receptors, and
they may support the chemical hypothesis that angina is
produced by local intramyocardial release of adenosine. How-
ever, it is still controversial and not known whether the effects
of aminophylline on cardiac pain in these studies were due to
alleviation of ischemia or to direct actions of aminophylline on
cardiac adenosine receptors.
Percutaneous transluminal coronary angioplasty (PTCA) is
widely used in treating patients with coronary artery disease
and serves as a useful model of clinical study. PTCA induces
alterations in hemodynamic status and metabolic function in
the myocardium during coronary artery occlusion (6–10). A
recent study (11) showed that cardiac pain experienced by
patients during PTCA might be caused by stretching of the
coronary artery wall, suggesting that mechanical stimuli may be
a mechanism of cardiac pain. However, it could be speculated
that endogenous adenosine, which is released from the isch-
emic myocardium during PTCA, may play an important role in
mediating the cardiac pain because PTCA increases purine
metabolites such as adenosine, hypoxanthine and uric acid
during balloon inﬂation (12). In the present study, therefore,
we investigated the effect of aminophylline on cardiac pain
during PTCA to assess the hypothesis that the stimulation of
P1 receptors by endogenous adenosine might be responsible
for cardiac pain during myocardial ischemia.
Methods
Patients. We studied 21 men who underwent balloon in-
ﬂation four times during PTCA. All 21 had one-vessel coro-
nary artery disease (75% reduction of internal diameter) at
the proximal two thirds of the left anterior descending coro-
nary artery. All had clinically stable effort angina with viable
myocardium as deﬁned by the development of typical cardiac
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pain with horizontal ST segment depression, 1 mm during
exercise testing and a reversible myocardial perfusion defect by
exercise thallium-201 scintigraphy. No patient had a previous
myocardial infarction, wall motion abnormality at rest by left
ventriculography, visible collateral circulation by coronary
angiography, left ventricular hypertrophy by electrocardiogra-
phy or echocardiography or conduction defects by electrocar-
diography. No patient had major complications related to the
PTCA procedure.
This was a single-blind, placebo-controlled, randomized
study. All patients were randomly allocated to one of two
groups. Group A consisted of 11 men, ranging in age from 53
to 72 years (mean 61), who received intravenously adminis-
tered aminophylline (5 mg/kg body weight) over a period of
5 min before the fourth balloon inﬂation. Group B consisted of
10 men, ranging in age from 55 to 69 years (mean 62), who
received intravenously administered saline solution over a
period of 5 min before the fourth balloon inﬂation. Standard
medications including long-acting nitrates, calcium channel
blockers and aspirin were continued on the day of the proce-
dure, but other medications including dipyridamole, beta-
adrenergic blocking agents, xanthine products and antidiabetic
sulfonylureas were discontinued at least 48 h before PTCA.
Written informed consent was obtained from all subjects.
PTCA procedure and study protocol. All patients were
premedicated with diazepam (2 mg orally) before the PTCA
procedure. After local anesthesia, coronary angiographic and
angioplasty catheters were inserted into a femoral artery. An
intravenous bolus of heparin (5,000 IU) was administered and
thereafter 2,000 IU of intravenous heparin was added every
1 h. All patients received isosorbide dinitrate before PTCA.
PTCA was performed with balloon catheters (balloon size 2.0
to 3.5 mm) that were chosen individually on the basis of the
diameter of normal segments adjacent to the stenosis. After
baseline angiography, the guide wire was placed across the
stenotic lesion. The balloon catheter was then placed within
the stenosis and the balloon inﬂated. After balloon deﬂation, a
period 5 min was allowed to reestablish baseline hemody-
namic and electrocardiographic conditions and to permit re-
covery from myocardial ischemia. Systemic blood pressure and
heart rate were simultaneously recorded during PTCA. The
PTCA procedure was considered to be successful when the
stenotic segment was dilated so that lumen narrowing was
50%.
The criteria for terminating the balloon inﬂation during
PTCA were as follows: 1) a subjective descriptive score of
cardiac pain7 points, as described later, 2) a balloon inﬂation
time 120 s, 3) a decrease in systolic blood pressure
20 mm Hg, and 4) frequent occurrence of premature ven-
tricular contractions. Because the balloon inﬂation time dif-
fered from the ﬁrst to the fourth ballooning, ST segment
elevation was assessed at the shortest balloon inﬂation time
among the four consecutive balloon inﬂations. As the hemo-
dynamic and electrocardiographic conditions returned to base-
line after the third balloon deﬂation, intravenous infusion of
aminophylline or saline solution was started and continued for
5 min. Then the balloon was inﬂated. For the fourth balloon
inﬂation, the balloon size and pressure were the same as those
used for the third inﬂation. The balloon was deﬂated according
to the termination criteria just described. The severity of
cardiac pain and hemodynamic variables during the fourth
inﬂation were assessed at the time equivalent to the balloon
inﬂation time of the third inﬂation.
Diameter of coronary arteries and angioplasty balloons.
The diameter of the coronary arteries before and after PTCA
and the diameter of the angioplasty balloons during balloon
inﬂation were quantitatively measured by computer analysis
with an automated edge contour detection method (Image
Analysis System, Kontron Cardio 500). The size of the guiding
catheter was used as a calibration scale to obtain measure-
ments in millimeters. The angiograms were assessed by two
independent observers who had no knowledge of the study
protocol.
Assessment of cardiac pain. At the beginning of the PTCA
procedure, patients were informed that cardiac pain might
develop. The severity of the pain was assessed on the basis of
scores ranging from 0/10 (no cardiac pain) to 10/10 (unbear-
able cardiac pain) (13). Patients were asked to describe the
pain score. In addition, the symptom-free interval (interval
from the start of the balloon inﬂation to the onset of balloon
inﬂation–induced pain) was measured to assess the pharmaco-
logic effect of agents on cardiac pain.
Assessment of electrocardiograms. Standard surface pre-
cordial leads and intracoronary electrocardiograms obtained
from the coronary guide wire were continuously monitored
and recorded at a paper speed of 25 mm/s throughout the
study. The electrocardiographic ST segment elevation was
measured 80 ms after the J point during each inﬂation. Then,
the sum of the ST segment elevations in precordial leads V1 to
V6 and ST segment elevations on intracoronary electrocardio-
grams were separately measured as an index of myocardial
ischemia and expressed in millimeters (1 mm  0.1 mV). ST
segment elevation measurements were compared at the short-
est balloon inﬂation time among the four consecutive balloon
inﬂations in each patient.
Analysis of plasma concentrations of aminophylline. Pe-
ripheral venous blood (7 ml) was obtained for the assay of
plasma aminophylline at the end of the PTCA procedure.
Plasma concentrations of aminophylline were determined ac-
cording to a previously described method with a modiﬁed
ﬂuorescence polarization immunoassay (TDx analyzer, Abbott
Laboratories) (14).
Statistical analysis. Values are expressed as mean value 
SD. The variables in Table 1 were compared by the unpaired
or paired Student t test. The reasons for balloon deﬂation
Abbreviations and Acronyms
ANOVA  analysis of variance
PTCA  percutaneous transluminal coronary angioplasty
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according to the termination criteria were compared by the
chi-square test between groups A and B. The magnitude of ST
segment elevation during ballooning was compared by re-
peated measures analysis of variance (ANOVA) with a post
hoc Scheffe´ test. The balloon inﬂation time, pain score and
duration of the symptom-free interval were analyzed by the
Wilcoxon signed rank test. Differences were considered statis-
tically signiﬁcant when p was 0.05.
Results
Clinical characteristics and hemodynamic variables. Clin-
ical characteristics in the two study groups are shown in Table
1. Groups A (aminophylline) and B (saline solution) were
similar in age and gender distribution. All patients had
successful PTCA. Coronary stenosis after PTCA was signiﬁ-
cantly reduced (p  0.01), and the two groups had a similar
degree of stenosis. In groups A and B, there was no difference
in balloon diameter or mean balloon pressure between the
third and the fourth inﬂation.
Hemodynamic variables during balloon inﬂation in the two
study groups are also shown in Table 1. In groups A and B, no
signiﬁcant difference was found in systolic and diastolic blood
pressure between the third and the fourth inﬂation. Heart rate
was higher during the fourth than during the third inﬂation in
group A (p  0.05), but did not differ between the third and
the fourth inﬂation in group B. The rate-pressure product was
similar between the third and the fourth inﬂation in both
groups. The plasma concentration of aminophylline was 6.0 
1.9 g/ml in group A, and it was not detectable in group B.
Termination of balloon inﬂation. The reasons for balloon
deﬂation according to the termination criteria are shown in
Table 2. In the ﬁrst three PTCA procedures, balloon inﬂation
was terminated because of cardiac pain in most patients.
During the fourth PTCA, balloon inﬂation was terminated
because of angina in 9 of 10 patients in group B, whereas in
group A it was terminated because of cardiac pain in only 3 of
11 patients and was terminated in 6 patients because balloon
inﬂation time exceeded 120 s.
ST segment changes. The shortest inﬂation time among
four consecutive balloon inﬂations was 71  20 and 72  23 s,
respectively, in group A and group B (p  0.96). Figure 1
summarizes the ST segment changes during balloon inﬂation
in the two study groups. In all patients in both groups, ST
segment elevation during all four balloon inﬂations was ob-
served in standard surface precordial and intracoronary elec-
trocardiograms. In the surface precordial electrocardiogram of
both groups, the ST segment elevation was greater during the
second than during the ﬁrst inﬂation (p  NS). ST segment
elevation during the third and the fourth balloon inﬂations was
signiﬁcantly smaller than that during the second inﬂation (p 
0.05). Furthermore, there were no differences in ST segment
elevation between the third and fourth inﬂations. The ST
segment elevation in the intracoronary electrocardiograms
during PTCA was similar to that observed in the surface
precordial electrocardiograms.
Cardiac pain during balloon inﬂation. All patients experi-
enced cardiac pain during PTCA. Figure 2 summarizes the
duration of the symptom-free interval during the third and





Age (yr) 61 6 62  5
Gender (% male) 100 100
Severity of stenosis (%)
Before PTCA 73.9 9.5 73.1  9.5





3rd inﬂation 2.9  0.4 / 9.2  2.5 2.9  0.4 / 7.9  1.9
4th inﬂation 2.9  0.5 / 9.5  2.3 3.0  0.5 / 8.8  2.2
SBP/DBP (mm Hg)
3rd inﬂation 144  20 / 82  12 140  20 / 78  13
4th inﬂation 142  12 / 82  9 140  21 / 76  13
Heart rate (beats/min)
3rd inﬂation 67 10 69  12
4th inﬂation 75  15† 70  11
RPP (beats/min  mm Hg)
3rd inﬂation 10,063 2,291 10,289  2,672
4th inﬂation 10,954 2,840 10,133  2,634
Venous aminophylline
concentration (g/ml)
6.0  1.9 Not detectable
*p  0.01 versus before PTCA. †p  0.05 versus 3rd inﬂation. Data
presented are mean value  SD or percent of patients. atm  atmosphere;
DBP  diastolic blood pressure; Group A  patients who received aminophyl-
line before the fourth inﬂation; Group B  patients who received saline solution
before the fourth balloon inﬂation; RPP  rate-pressure product; PTCA 
percutaneous transluminal coronary angioplasty; SBP  systolic blood pressure.
Table 2. Incidence of Balloon Deﬂation

















Pain score 7 points 8 8 10 8 10 7 3* 9
Balloon inﬂation time 120 s 2 1 0 1 1 1 6* 0
Premature ventricular contractions 1 1 1 1 0 2 2 0
Decrease in SBP 20 mm Hg 0 0 0 0 0 0 0 1
*p  0.05 versus Group B. Data presented are number of patients. Abbreviations as in Table 1.
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fourth balloon inﬂations in groups A and B. In group A, the
symptom-free interval was signiﬁcantly longer during the
fourth (64  27 s) than during the third inﬂation (42  13 s,
p  0.05). In group B, the duration of this interval was similar
in the two inﬂations (p  0.37). Figure 3 shows balloon
inﬂation time during the third and in fourth balloon inﬂations.
In group A, the inﬂation time was signiﬁcantly longer during
the fourth (103  20 s) than during the third inﬂation (79 
23 s, p 0.05). In group B, the inﬂation time was similar in the
two inﬂations (p 0.67). Figure 4 shows the severity of cardiac
pain during the third and fourth balloon inﬂations. In group A,
the severity of cardiac pain was less during the fourth (4.6 
2.3) than during the third inﬂation (7.6  1.4, p  0.01). In
group B, the severity of the cardiac pain was similar in both
inﬂations (p  0.78).
Discussion
In the present study, performed in men with clinically stable
effort angina undergoing PTCA, intravenous infusion of amin-
Figure 1. Bar graphs of ST segment elevation on the standard
electrocardiogram (surface ECG) and intracoronary electrocardio-
gram (ic ECG) during the four balloon inﬂations. In group A
(aminophylline infusion) and group B (saline infusion), ST segment
elevation during the third and fourth balloon inﬂations was signiﬁ-
cantly smaller than that during the second inﬂation. There were no
differences in ST segment elevation between the third and fourth
inﬂations. *p  0.05 versus second inﬂation.
Figure 2. Plots of duration of the symptom-free interval (from the
beginning of inﬂation to the onset of cardiac pain) during the third and
the fourth balloon inﬂations in the two study groups. In group A,
aminophylline administration signiﬁcantly prolonged the symptom-
free interval during the fourth balloon inﬂation, whereas saline
solution did not in group B. Closed circles and bars indicate mean
value  SD.
Figure 3. Plots of the balloon inﬂation time during the third and the
fourth balloon inﬂations in the two study groups. In group A,
aminophylline administration signiﬁcantly prolonged the balloon inﬂa-
tion time during the fourth balloon inﬂation, whereas saline solution
did not in group B. Closed circles and bars indicate mean value  SD.
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ophylline, a potent antagonist of the adenosine P1 receptor,
reduced the severity of cardiac pain and prolonged the
symptom-free interval during balloon inﬂation, although the
magnitude of ST segment elevation did not change between
the third and fourth inﬂations, thus indicating a similar degree
of myocardial ischemia in the two inﬂations. These ﬁndings
therefore suggest that endogenous adenosine may play an
important role in mediating cardiac pain through the stimula-
tion of adenosine P1 receptors.
Methodologic considerations. PTCA is accompanied by
alterations in myocardial metabolism and hemodynamic status
(6–10). In the present study, several methodologic issues
should be considered before concluding that aminophylline
was effective in alleviating cardiac pain during PTCA, indepen-
dent of the degree of myocardial ischemia. 1) In animals,
ischemic preconditioning—that is, adaptation to myocardial
ischemia—occurs in response to repetitive episodes of myo-
cardial ischemia; that is, brief periods of myocardial ischemia
induced by coronary occlusion enhance the tolerance to sub-
sequent ischemic episodes (15–17). Ischemic preconditioning
occurs in clinical settings as well. In patients undergoing PTCA
(11,18), subjective anginal discomfort, ST segment elevation
and myocardial lactate production are less during the second
than during the ﬁrst balloon inﬂation. To avoid the inﬂuence of
ischemic preconditioning on the interpretation of our results,
we enrolled only patients who underwent balloon inﬂation four
times. In the present study, ST segment elevation during the
third balloon inﬂation was signiﬁcantly less than that during
the second inﬂation. Furthermore, in group B (saline solution)
the ST segment elevation, the duration of the symptom-free
interval, balloon inﬂation time and the severity of cardiac pain
were similar in the third and fourth inﬂations. Thus, it is likely
that ischemic preconditioning had already been established
during the third inﬂation in this study. 2) Tomai et al. (11)
recently demonstrated that the severity of cardiac pain in-
creased when the pressure used during the second balloon
inﬂation was higher than that used during the ﬁrst inﬂation,
and they suggested that cardiac pain experienced by patients
was caused in part by stretching of the coronary artery wall
during balloon inﬂation. In the present study, the balloon
diameter and pressure during the third and fourth inﬂations
were similar. Accordingly, the mechanical effect of the stretch-
ing by balloon inﬂation may have been similar during the third
and fourth inﬂations. It is therefore unlikely that alleviation of
cardiac pain by aminophylline was due to less mechanical
distortion and stretching of sensory cardiac nerves located in
the vascular adventitia during the fourth than during the third
inﬂation. 3) The reasons for termination of balloon inﬂation
should be considered. During the ﬁrst three inﬂations, the
inﬂation was usually terminated because of cardiac pain in
both groups. During the fourth inﬂation, it was primarily
terminated because of cardiac pain in group B, but in group A,
it was terminated because of cardiac pain in only three patients
and because of a long balloon inﬂation time in six. These
results indicate that during the fourth balloon inﬂation patients
in group A had greater tolerance of cardiac pain than did those
in group B.
ST segment elevation during the ﬁrst balloon inﬂation is
usually maximal, and the magnitude is reduced with subse-
quent ischemic episodes (11,18). However, in the present
study, ST segment elevation during the ﬁrst inﬂation was
smaller (p  NS) than that during the second inﬂation in both
groups A and B. Similar results were reported by others (19).
Although the reasons are unclear, this difference was not due
to balloon inﬂation time because ST segment deviation was
assessed at the shortest balloon inﬂation time among the four
consecutive balloon inﬂations. A possible reason is that isch-
emic preconditioning may not have been established during
the ﬁrst inﬂation because the inﬂation time was shorter (71 and
72 s) in this study than that (90 and 120 s) in previous studies
(11,18).
Adenosine and cardiac ischemic pain. In experimental
studies, endogenous adenosine is shown to be an indicator of
myocardial ischemia because the amount of adenosine pro-
duced is closely linked to the oxygen supply demand ratio in
the heart (20). Although we did not quantitatively measure the
release of endogenous adenosine during PTCA, a recent study
(12) clearly demonstrated that coronary sinus concentrations
of adenosine are signiﬁcantly augmented in close proportion to
the balloon inﬂation time during PTCA. In the present study,
we assumed that endogenous adenosine released during PTCA
might play an important role in mediating anginal pain during
myocardial ischemia. To test this hypothesis, we examined the
effects of aminophylline infusion on cardiac pain during PTCA.
Adenosine receptors are classiﬁed as P1 and P2 receptors.
Aminophylline is a potent P1 receptor antagonist. Our ﬁnding
that aminophylline signiﬁcantly reduced the severity of cardiac
pain during PTCA without affecting ST segment elevation
Figure 4. Plots of the severity of cardiac pain during the third and the
fourth balloon inﬂations in the two study groups. In group A,
aminophylline administration signiﬁcantly reduced the severity of
cardiac pain during the fourth balloon inﬂation, whereas saline solu-
tion did not in group B. Closed circles and bars indicate mean value
SD.
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suggests that the stimulation of P1 receptors by endogenous
adenosine may be partially responsible for cardiac pain during
myocardial ischemia. Our results are consistent with those
reported by Crea et al. (5), who demonstrated that aminophyl-
line decreased the severity of exercise-induced cardiac pain
without affecting myocardial ischemia. Thus, our ﬁndings may
support their concept that the adenosine P1 receptor is respon-
sible for cardiac pain during ischemia in experimental (21) and
clinical (5) studies. Because aminophylline did not completely
alleviate cardiac pain during PTCA, it is possible that other
chemical mediators such as adenosine P2 receptors, bradykinin
(22,23) and others may have been responsible for cardiac pain.
We did not examine this possibility because it was beyond the
scope of the present study.
In previous studies, pretreatment with bamiphylline, an A1
adenosine receptor blocker, prevented the decrease in chest
pain and ST segment shift during the second balloon occlusion
(24) and pretreatment with aminophylline abolished the adap-
tation to repeated balloon inﬂations (19). These ﬁndings
suggest that an A1 receptor blockade abolishes ischemic pre-
conditioning during PTCA. However, ST segment elevation
did not differ between the third and fourth inﬂations in our
group A, suggesting that aminophylline did not abolish isch-
emic preconditioning in our study. Although reasons for these
differences are unclear, differences in the time of injection of
aminophylline may have played a role; that is, the agent was
given after the establishment of the ischemic preconditioning
in our study and before in the other studies.
Adenosine causes vasodilation of coronary microvessels
and the coronary steal phenomenon in patients with ischemic
heart disease. In previous clinical (25–28) and dog (28–30)
studies, aminophylline or bamiphylline was shown to lessen
myocardial ischemia. These observations suggest that the
anti-ischemic action of these agents may be related to the
improvement of the coronary steal phenomenon elicited by
adenosine released during myocardial ischemia. In the present
study performed in patients with no evidence of collateral
circulation, aminophylline signiﬁcantly prolonged balloon in-
ﬂation time and duration of the symptom-free interval during
inﬂation. Thus, it is possible that aminophylline alleviated
cardiac pain by reducing ischemia but not by affecting sensory
nerve endings. However, the ST segment elevation measured
in the surface and intracoronary electrocardiograms was sim-
ilar during the third and fourth balloon inﬂations, as was the
rate-pressure product as an index of myocardial oxygen de-
mand. Thus, the possibility that aminophylline decreased the
severity of cardiac pain by alleviating ischemia is small in this
study.
Conclusions. The present study, to our knowledge, pro-
vided the ﬁrst demonstration that aminophylline, a potent
antagonist of adenosine P1 receptors, signiﬁcantly reduced the
severity of cardiac pain during PTCA independently of the
degree of myocardial ischemia. These ﬁndings may imply that
the activation of P1 receptors by endogenous adenosine is
partially responsible for cardiac pain during myocardial isch-
emia.
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